Thus, LILRB2 mAb-mediated blockade demonstrates a capacity for TAM reprogramming, in addition to potentially suppressing ‘don’t eat me’ signaling derived from interactions with HLA class I on cancer cells. Here, LILRB2 is linked to cancer.